Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy - CRCL-Sénescence, cancer et vieillissement
Article Dans Une Revue Molecular Biomedicine Année : 2023

Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy

Résumé

Pancreatic cancer is one of the deadliest cancers owing to its late diagnosis and of the strong resistance to available treatments. Despite a better understanding of the disease in the last two decades, no significant improvement in patient care has been made. Senescent cells are characterized by a stable proliferation arrest and some resistance to cell death. Increasing evidence suggests that multiple lines of antitumor therapy can induce a senescent-like phenotype in cancer cells, which may participate in treatment resistance. In this study, we describe that gemcitabine, a clinically-used drug against pancreatic cancer, induces a senescent-like phenotype in highly chemoresistant pancreatic cancer cells in vitro and in xenografted tumors in vivo. The use of ABT-263, a well-described senolytic compound targeting Bcl2 anti-apoptotic proteins, killed pancreatic gemcitabine-treated senescent-like cancer cells in vitro. In vivo, the combination of gemcitabine and ABT-263 decreased tumor growth, whereas their individual administration had no effect. Together these data highlight the possibility of improving the efficacy of conventional chemotherapies against pancreatic cancer by eliminating senescent-like cancer cells through senolytic intervention. Further studies testing different senolytics or their combination with available treatments will be necessary to optimize preclinical data in mouse models before transferring these findings to clinical trials.
Fichier principal
Vignette du fichier
43556_2023_Article_116.pdf (2.17 Mo) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04113411 , version 1 (21-08-2023)

Identifiants

Citer

Sara Jaber, Marine Warnier, Christopher Leers, Mathieu Vernier, Delphine Goehrig, et al.. Targeting chemoresistant senescent pancreatic cancer cells improves conventional treatment efficacy. Molecular Biomedicine, 2023, 4 (1), pp.4. ⟨10.1186/s43556-023-00116-4⟩. ⟨hal-04113411⟩
124 Consultations
48 Téléchargements

Altmetric

Partager

More